Status
Conditions
Treatments
Study type
Funder types
Identifiers
About
This clinical trial studies how well a long-term follow-up works in patients with prostate cancer after surgery. Long-term follow-up data may serve as a resource to help ask clinical questions, describe health-related quality of life and long-term complications related, and facilitate future studies focusing on interventions to improve health status and health-related quality of life in prostate cancer survivors.
Full description
PRIMARY OBJECTIVES:
I. To provide comprehensive long-term follow-up care to prostate cancer survivors at the City of Hope who underwent definitive surgical therapy.
II. To use the information obtained from follow-up of prostate cancer survivors who underwent definitive surgical therapy to serve as a resource that will help answer clinical questions, generate and test hypotheses, describe the incidence of long-term complications, and facilitate future studies focusing on interventions for long-term complications of prostate cancer and its therapy.
III. To use the information gained from follow-up of prostate cancer survivors who underwent definitive surgical therapy to describe health-related quality of life (HRQL) concerns and to serve as a resource to facilitate future studies focusing on interventions to improve health status and HRQL in prostate cancer survivors.
OUTLINE:
Patients undergo long-term follow-up and receive a written survivorship care plan including comprehensive health evaluation and health education beginning 1 year post surgery.
Enrollment
Sex
Volunteers
Inclusion criteria
Diagnosis of prostate cancer
Treated with a definitive surgical procedure at City of Hope
At least one year post surgical treatment for prostate cancer
No history of recurrent, progressive, or metastatic disease
Currently stable disease or no evidence of disease
No prior treatment of prostate cancer with radiation or chemotherapy
No history of other urologic cancer (e.g., bladder cancer, renal cell carcinoma) in addition to prostate cancer
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
2,500 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal